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The aim of this study was to evaluate the possibility of preparing dexamethasone-loaded starch-based porous matrices in a one-step
process. Supercritical phase inversion technique was used to prepare composite scaﬀolds of dexamethasone and a polymeric blend of
starch and poly(L-lactic acid) (SPLA) for tissue engineering purposes. Dexamethasone is used in osteogenic media to direct the diﬀeren-
tiation of stem cells towards the osteogenic lineage. Samples with diﬀerent drug concentrations (5–15 wt.% polymer) were prepared at
200 bar and 55 C. The presence of dexamethasone did not aﬀect the porosity or interconnectivity of the polymeric matrices. Water
uptake and degradation studies were also performed on SPLA scaﬀolds. We conclude that SPLA matrices prepared by supercritical
phase inversion have a swelling degree of nearly 90% and the material presents a weight loss of 25% after 21 days in solution. Further-
more, in vitro drug release studies were carried out and the results show that a sustained release of dexamethasone was achieved over
21 days. The ﬁtting of the power law to the experimental data demonstrated that drug release is governed by an anomalous transport,
i.e., both the drug diﬀusion and the swelling of the matrix inﬂuence the release of dexamethasone out of the scaﬀold. The kinetic constant
was also determined. This study reports the feasibility of using supercritical ﬂuid technology to process in one step a porous matrix
loaded with a pharmaceutical agent for tissue engineering purposes.
 2009 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.
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Tissue engineering is a promising therapeutic approach
that combines cells, biomaterials, and bioactive com-
pounds [1,2]. The emerging next generation of engineered
tissues relies on the development of loaded scaﬀolds con-
taining bioactive molecules in order to control the cellular
function (e.g. growth or diﬀerentiation factors) or to act on
the surrounding tissues (e.g. drugs such as anti-inﬂamma-1742-7061/$ - see front matter  2009 Acta Materialia Inc. Published by Else
doi:10.1016/j.actbio.2009.01.047
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mater (2009), doi:10.1016/j.actbio.2009.01.047tory agents or antibiotics) [3,4]. Hence, the strategy is to
mimic matrix and provide the necessary information or sig-
naling for cell attachment, proliferation and diﬀerentiation
to meet the requirement of dynamic reciprocity for tissue
engineering. This justiﬁes the importance of drug delivery
in tissue engineering applications [5,6].
Small molecular weight drugs that control proliferation
and diﬀerentiation of cells can be incorporated into biode-
gradable scaﬀolds to induce cellular diﬀerentiation and tis-
sue remodeling. The scaﬀold therefore plays an important
role not only as a physical support but also in the cell pro-
liferation and diﬀerentiation [7]. Dexamethasone is a rele-
vant bioactive compound to be used in bone tissue
engineering applications. This drug is used in osteogenic
media to direct the diﬀerentiation of stem cells towardsvier Ltd. All rights reserved.
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has been used for the preparation of scaﬀolds, from metals
to ceramics and polymers. Synthetic biodegradable poly-
mers have been widely used for tissue engineering. How-
ever, natural polymers have unique, intrinsic properties
that make them appealing to be used as scaﬀolds [11].
Natural polymers are in general non-toxic, even in large
concentrations, mucoadhesive, biocompatible, and biode-
gradable [11–13].
Starch-based polymers have been studied in our group
for a wide range of bone-related therapy applications,
ranging from tissue engineering scaﬀolds [14–17], to bone
cements [18,19] and drug delivery systems [20,21]. Their
natural origin, together with their mechanical properties
and biocompatibility, support the potential of starch-based
materials in the biomedical ﬁeld. Our group has reported
the success of starch-based microparticles, from starch-
poly(L-lactic acid) (SPLA), to act as controlled delivery
devices [22]. SPLA microparticles loaded with corticoste-
roids were able to release the drug up to 30 days.
One of the most important stages of tissue engineering is
the design and processing of a porous 3D structure, with
high porosity, high interconnectivity and uniform distribu-
tion. Conventionally, three-dimensional structures can be
obtained by processes such as solvent casting-particle
leaching [23], freeze-drying-particle leaching [24], thermally
induced phase separation [25], compression moulding [26],
injection moulding [27], extrusion [28], foaming [29], wet
spinning [30], electrospinning [31], among others [32]. The
main disadvantages of these methods are the use of large
quantities of organic solvents or high temperatures. Super-
critical ﬂuids have been proposed as excellent alternatives
to the conventional processes for polymer processing [33–
35].
The supercritical-assisted phase inversion method is one
of the proposed alternatives to reduce the use of large
quantities of organic solvents. Diﬀerent techniques have
been proposed for the preparation of scaﬀolds for tissue
engineering, namely gas foaming or phase inversion [36].
Gas foaming takes advantage of the plasticizing properties
of carbon dioxide. In this technique, the polymer is
exposed to carbon dioxide, which plasticizes it by reducing
the glass transition temperature or melting point. On vent-
ing the CO2 by depressurization, thermodynamic instabil-
ity causes supersaturation of the carbon dioxide dissolved
in the polymer matrix and hence nucleation of cells occurs
[37]. This technique is limited by the high glass transitions
of the crystalline polymers and is therefore more common
to amorphous polymers.
The phase inversion method involves casting of a poly-
mer solution onto an inert support followed by immersion
of the support with the cast ﬁlm into a bath ﬁlled with a
non-solvent for the polymer. The contact between the sol-
vent and the non-solvent causes the solution to be phase-
separated. Several advantages exist if the non-solvent used
is a supercritical ﬂuid. One of the most important advanta-
ges of the use of carbon dioxide is the fact that simply byPlease cite this article in press as: Duarte ARC et al., Dexamethasone
mater (2009), doi:10.1016/j.actbio.2009.01.047tuning the processing conditions, i.e. pressure and temper-
ature, one can tailor the ﬁnal structure of the product.
Additionally, when carbon dioxide is used as a non-solvent
a subsequent drying step is avoided and the porous struc-
ture obtained is a dry product free of any residual solvent.
Carbon dioxide is the most commonly used supercritical
ﬂuid as it has mild critical parameters, it is environmentally
benign, non-toxic, non-ﬂammable, non-corrosive, ready
available and inexpensive. Its elimination and the recovery
of ﬁnal products are easier (no residue is left and a dry solid
product is easily obtained, just by controlling the pressure),
leading to processes with less energy consumption [38].
The use of carbon dioxide as a non-solvent for phase
separation has been successfully reported in the literature,
for example for PLLA [39,40], PMMA [41], Nylon 6 [42],
PS [43], cellulose acetate [44,45], polysulfone [46,47] and
polycarbonate/PEG [48]. Recently we have proposed the
use of a supercritical-assisted process for the preparation
of scaﬀolds from natural sources [49]. A starch-based blend
(SPLA) was successfully processed by supercritical-assisted
phase inversion method.
To our knowledge the use of a supercritical phase inver-
sion technique for the preparation of composite matrices
loaded with a bioactive agent is for the ﬁrst time reported
in this work. In this study, the possibility of preparing in
a one-step process a porous matrix loaded with an active
compound is evaluated. This methodology could open
other possibilities of developing substrates for tissue engi-
neering or bioengineering applications, where processing
of biomaterials and incorporation of bioactive agents are
combined using supercritical ﬂuid technologies.
2. Experimental procedure
2.1. Materials
A commercial blend of starch and poly-(L-lactic acid)
(SPLA 50:50) was supplied by Novamont. Dexamethasone
(CAS 50-02-2, 98% purity) was purchased from Sigma and
chloroform, (CAS 67-68-5, 99.9% purity) was purchased
from Vaz Pereira. Carbon dioxide (99.998 mol.%) was sup-
plied by Air Liquide. All chemicals were used with no fur-
ther puriﬁcation.
2.2. Supercritical-assisted phase inversion process
The phase inversion experiments were carried out in an
apparatus specially designed and built for this work. The
set up is schematically presented in Fig. 1 [49].
SPLA 50:50 is mixed with dexamethasone and dissolved
in chloroform. This procedure was performed separately
for each of the ratios of bioactive agent and polymer (5,
10 or 15% wt./wt. (dexamethasone:polymer). In each
experiment a small amount (ca. 2 ml) of the polymer solu-
tion is loaded in a stainless steel cap 2 cm in diameter,
which is placed inside the high pressure vessel. The vessel
is heated (to 55 C) by means of an electric thin band hea--loaded scaﬀolds prepared by supercritical-assisted ..., Acta Bio-
Fig. 1. Schematic diagram of the high pressure phase inversion apparatus
(P, pressure transducer; TIC, temperature controller; FM, ﬂowmeter;
BPR, back pressure regulator).
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maintains temperature within ±1 C (TC). Carbon dioxide
is pumped into the vessel, at a constant ﬂow rate of 5 g
min1, using a high pressure piston pump (P-200A Thar
Technologies) until the operational pressure (200 bar) is
attained. The pressure inside the vessel is measured with
a pressure transducer (P). The system was closed for
45 min to allow the occurrence of phase separation. After-
wards the system is ﬂushed for another 45 min, with a
stream of carbon dioxide at very low ﬂow rate (5 g min1),
in order to ensure complete drying of the scaﬀolds. The
ﬂow is regulated by a ﬂow meter (FM – Siemens,
SITRANS FC MASS FLO MASS2100). The outﬂow is
regulated by a back pressure valve (Go Inc., USA).
2.3. Scaﬀold characterization
2.3.1. Scanning electron microscopy
Samples of the scaﬀolds prepared were observed by a
Leica Cambridge S360 scanning electron microscope
(SEM). The matrices were ﬁxed by mutual conductive
adhesive tape on aluminium stubs and covered with gold
using a sputter coater.
2.3.2. Micro-computed tomography (micro-CT)
The inner structure, porosity and interconnectivity were
evaluated by micro-computed tomography using a Scanco
20 equipment (Scanco Medicals, Switzerland) with penetra-
tive X-rays of 40 keV. The X-ray scans were acquired in
high-resolution mode (39.39 lm). CT Analyser (SkyScan,
Belgium) was used to visualize the 2D X-ray sections
images of the scaﬀolds.
2.3.3. Fourier transform infrared analysis (FTIR)
This was performed to the scaﬀolds loaded with dexa-
methasone. Spectra were recorded at 32 scans with a reso-
lution of 2 cm1 (Shimadzu – IRPrestige 21).
2.4. Water uptake and degradation
The swelling capability of the matrices prepared was
accessed by measuring the water uptake of the samplesPlease cite this article in press as: Duarte ARC et al., Dexamethasone
mater (2009), doi:10.1016/j.actbio.2009.01.047for a period up to 22 days. Scaﬀolds of SPLA 50:50 pre-
pared by supercritical phase inversion were weighed and
immersed 10 ml of an isotonic solution at pH 7.4. The sam-
ples were placed in a water bath at 37 C. After predeter-
mined periods of time (1, 3, 7, 14 and 22 days) the
samples were weighed in order to determine the water
uptake of the scaﬀolds.
Water uptake was determined using the following
equation:
% water uptake ¼ ww  wi
wi
 100 ð1Þ
where ww is the weight of the wet sample and wi is the
weight of the initial sample.
After each time period the samples were dried and
weighed to determine the weight loss, which was calculated
according to the equation:
% weight loss ¼ wf  wi
wi








 100 ð2Þ
where wf is the ﬁnal weight of the dry sample after immer-
sion and wi is the initial weight of the sample.
The pH of each solution was also measured in order to
determine the eﬀect of polymer degradation on the acidity
of the medium.
The data presented are the result of the average of at
least ﬁve measurements.
2.5. In vitro release studies
Dexamethasone-loaded SPLA scaﬀolds were weighed
(averageweight 9 ± 0.3 mg) and suspended in 10 ml of phos-
phate buﬀer solution stirred at 60 rpm at 37 C. Aliquots of
500 ll were withdrawn in predetermined time intervals and
the same volume of fresh medium was added to the suspen-
sion. The samples were analysed by UV–vis spectroscopy
at 242 nm (Shimazu UV 1601). The results presented are
an average of three measurements. Calculations of the
amount of drug released took into account the replacement
of aliquots with fresh medium.3. Mathematical modelling of drug release
Knowledge of the mass transport mechanisms and the
kinetics of the drug release is essential for the design of
new drug delivery systems. Several models from simple
empirical or semi-empirical to more complex mechanistic
theories have been proposed to describe drug release from
delivery systems.
Higuchi derived a very simple empirical equation (3)
describing the rate of release of solid drugs under
pseudo-steady-state assumptions [50]. This relationship
demonstrates the linearity between the release rate and
the square root of time:
Mt
M1
¼ K ﬃﬃtp ð3Þ-loaded scaﬀolds prepared by supercritical-assisted ..., Acta Bio-
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inﬁnite time and K is a kinetic constant [51]. An exact solu-
tion of Fick’s law of diﬀusion describes the proportionality
between the fractional amount of drug released and the
square root of time and can be written in a similar way
to Eq. (1). The validity of these equations is, however, only
valid up to 60% of the total amount of drug (M1).
Although both Higuchi and Fick equations have the
same mathematical expression and describe the same
behaviour, there is a major distinction between their
assumptions. Nevertheless, in both cases diﬀusion is the
dominating mass transport mechanism and the drug
release is diﬀusion-controlled.
Another case is one where the drug release rate is inde-
pendent of time, i.e., it corresponds to a zero-order kinet-
ics. Many situations of release processes fall between
these cases, the Fickian diﬀusion and the zero-order kinet-
ics. An heuristic equation, known as power law, that trans-
lates this behaviour, can be written as [52,53]:
Mt
M1
¼ ktn ð4Þ
where k is a constant and n is the diﬀusional exponent,
which is indicative of the transport mechanism. Like Eq.
(3), this relationship is only valid for the ﬁrst 60% of the
drug released.
4. Results and discussion
4.1. Synthesis of dexamethasone-loaded SPLA scaﬀolds
In this study the possibility of preparing dexametha-
sone-loaded SPLA scaﬀolds with potential application in
tissue engineering using supercritical ﬂuid technology was
evaluated. Supercritical-assisted phase inversion technique
presents some advantages over the conventional phase
inversion process, namely the fact that porosity and inter-
connectivity are induced in the samples at the same time
that the material is precipitated from the organic solvent.
Furthermore, the material is recovered in the dry state,
which avoids the use of any additional drying steps, reduc-
ing the processing energy consumption and leading to more
eﬃcient processes. From the matrix prepared, smaller
cylindrical samples were cut with an average height of
1.7 mm and an average diameter of 4 mm. Scaﬀolds with
three diﬀerent drug concentrations were prepared, namelyFig. 2. SEM images of the scaﬀolds prepared at 200 bar and 55 C with 15% p
and (c) dexamethasone 15wt.%.
Please cite this article in press as: Duarte ARC et al., Dexamethasone
mater (2009), doi:10.1016/j.actbio.2009.01.0475, 10 and 15% wt./wt. (drug:polymer). Samples were pre-
pared at 55 C and 200 bar and the morphology of the
matrices was evaluated by SEM analysis (Fig. 2).
The synthesis of SPLA scaﬀolds loaded with dexameth-
asone leads to structures with similar morphologies to the
unloaded scaﬀolds. Therefore, the impregnation of dexa-
methasone does not seem to produce signiﬁcant changes
in the morphology of the polymeric structures. The SPLA
matrices obtained by supercritical-assisted phase inversion
are bicontinuous structures characterized by a rough sur-
face where micropores and macropores are visible. Such
particular microstructure enhances the transport properties
within the structure and could also encourage cell attach-
ment and proliferation. The matrices are also characterized
by a highly interconnected porous structure.
Micro-computed tomography allows a better visualiza-
tion of the inner structure of the matrices prepared. An
example of the 3D model of a loaded SPLA matrix pre-
pared by supercritical-assisted phase inversion method is
shown in Fig. 3.
Fig. 3a demonstrates that the porous structure exhibits a
signiﬁcant porosity and interconnectivity is throughout all
the volume of the sample. The porosity of the sample was
calculated to be 66%. The representative 2D slice in
Fig. 3b shows the macropores (200 lm) and the microp-
ores (ranging from 20 to 50 lm) of the sample.
The presence of dexamethasone in the scaﬀolds was con-
ﬁrmed by the FTIR analysis. Fig. 4 shows the spectra for
the scaﬀolds of SPLA and SPLA loaded with dexametha-
sone. The characteristic peaks of dexamethasone at 900
and 1650 cm–1 can also be observed in the scaﬀolds pre-
pared with the diﬀerent amounts of drug. This conﬁrms
the presence of drug in the matrix. The relative intensity
of these peaks with respect to the SPLA bands increases
with increasing dexamethasone content.
4.2. Water uptake and degradation studies
Both the hydration degree and the degradation behav-
iour are the most important properties of the materials
when they are aimed to be used in biomedical or environ-
mental applications, as their lifetime will be governed by
these two processes which are intimately correlated. For
biodegradable polymers degradation occurs as a result of
natural biological processes or other factors such as hydro-
lysis. Additionally, the drug release rate is mostly inﬂu-olymer in solution: (a) dexamethasone 0wt.%; (b) dexamethasone 5wt.%;
-loaded scaﬀolds prepared by supercritical-assisted ..., Acta Bio-
Fig. 3. Representative micro-CT images of SPLA matrix prepared at
200 bar and 55 C (10wt.% dexamethasone): (a) 3D model and (b) 2D
model.
Fig. 4. FTIR spectra of dexamethasone, SPLA 50:50, dexamethasone-
loaded SPLA at 5wt.%, 10wt.% and 15wt.%.
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Fig. 5. Water uptake proﬁle of SPLA 50:50 porous scaﬀolds prepared by
supercritical phase inversion.
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scaﬀold and the water uptake of the polymeric matrix.
For these reasons and for the preparation of systems for
controlled release applications, the knowledge of water
uptake and degradation is relevant.
In order to evaluate the swelling of the porous matrix,
water uptake studies on unloaded SPLA scaﬀolds were car-
ried out. Fig. 5 presents the percentage of water uptake of
the matrix as a function of time.
A great fraction of the water uptake corresponds to the
water that is found in the macropores of the scaﬀolds. The
scaﬀolds obtained by supercritical-assisted phase inversion
exhibit diﬀerent water uptakes, as compared to samples
obtained by other processing techniques reported in the lit-
erature [54,55]. This is probably due to the high porosity
and interconnectivity achieved with this method. Previous
studies from our group, on starch-based polymers, have
shown that the diﬀerence in water uptake and degradation
of scaﬀolds from the same polymer might be due to the dif-
ferent processing technologies [56]. The properties of the
3D scaﬀold have a more relevant role in the swelling andPlease cite this article in press as: Duarte ARC et al., Dexamethasone
mater (2009), doi:10.1016/j.actbio.2009.01.047degradation of the matrix than the polymer itself. The limit
value for the water uptake should be regarded as a result of
two complementary phenomena: the intrinsic water uptake
capability of the material (related to the chemical composi-
tion and crystallinity) and the degradation history of the
material. These phenomena are somewhat inter-related.
This is the main reason why the water uptake should be
discussed along with the weight loss behaviour [57]. Water
uptake experiments give some indication also on the degra-
dation of the sample itself. We can observe in Fig. 4 that
the water uptake increases from the ﬁrst to the third day
but afterwards there is a decrease in the swelling of the
polymer. This can be due to the degradation of the mate-
rial. During degradation the mass of material may undergo
changes and these changes can be monitored by compari-
son of the mass before and after the degradation period.
Fig. 6 shows the weight loss of the material as a function
of time.
After implantation, biomaterials interact with surround-
ing ﬂuids by ﬁrst absorbing water, which initiates their deg-
radation process. The absorption of water makes the
material more ﬂexible and might cause dimensional
changes. Moreover, higher water absorption usually accel--loaded scaﬀolds prepared by supercritical-assisted ..., Acta Bio-
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Fig. 6. Weight loss proﬁle of SPLA 50:50 porous scaﬀolds prepared by
supercritical phase inversion.
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water uptake in the mechanical and viscoelastic properties
of the SPLA scaﬀolds was analysed in another work [58].
The scaﬀolds’ porosity will have direct inﬂuence in the ease
of retention and access of the degradation solution in the
bulk of the material, which will therefore inﬂuence their
degradation behaviour. The weight loss of the SPLA sam-
ples prepared by supercritical-assisted phase inversion is
reduced by about 25% in 3 days. This weight loss is mainly
due to the leaching of small particles that can detach from
the scaﬀold as it is immersed in water, in the beginning of
the experiment. That is to say that the biodegradation of
the polymer itself does not have this degradation rate. This
is supported by the fact that after 3 days and until 22 days
no major changes in weight loss were observed. The high
porosity and interconnectivity of the SPLA matrix pre-
pared helps to understand this behaviour. The scaﬀold pre-
sents a maximum water uptake that is reached after 3 days
of immersion. The diﬀusion of water into the bulk of the
matrix weakens the structure, which is susceptible to a fas-
ter degradation. However, after this period no major
changes were observed in the swelling and in the weight
loss of the polymer within the time range analysed.
One of the eﬀects of polymer hydrolysis is the change in
the acidity of the media. Fig. 7 represents the trend of the
pH of the media as polymer degradation occurs.7
7.1
7.2
7.3
7.4
7.5
0 5 10 15 20 25
time (days)
pH
Fig. 7. pH proﬁle of the isotonic solution where the SPLA 50:50 porous
scaﬀolds, prepared by supercritical phase inversion (200 bar and 55 C)
were immersed.
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mater (2009), doi:10.1016/j.actbio.2009.01.047The pH of the solution decreases with time from 7.4 to
7.19. The knowledge and the control of the pH of the solu-
tion are important when we are considering the matrix for
drug release purposes. The solubility of a drug in an aque-
ous environment is dependent on the pH of the solution,
thus drug release rate will also vary according to this
parameter. However, the eﬀect of polymer degradation
on the acidity of the solution is, in this case, and for the
period of time of this study (22 days), not signiﬁcant.
4.3. In vitro release studies
For tissue engineering of bone from stem cells, medium
composition can guide diﬀerentiation along the ostogenic
lineage. Glucocorticoids, such as dexamethasone, are
added routinely in osteogenic medium as they are shown
to have stimulatory eﬀects on skeletal cells. It has also been
suggested that the exposure of stem cells to dexamethasone
may be eﬀective in inducing and maintaining the osteoblas-
tic phenotype [59–61]. The precise control of the drug
release from the composite scaﬀolds prepared is the main
goal of the systems prepared. In Fig. 8, the release of dexa-
methasone from the SPLA scaﬀolds is shown.
The proﬁle is very similar for the three concentrations
studied, as it would be expected since the polymeric matrix,
which gives support to the drug, is the same. The release of
drug from the scaﬀolds loaded with 10 and 15wt.% of dexa-
methasone tends to the same value and a possible explana-
tion for this might be the poor solubility of the drug in
aqueous media.
In the case of the SPLA scaﬀolds loaded with 5wt.%
dexamethasone, one can observe from the release proﬁle
that, in fact, nearly 8wt.% was impregnated. This might
point to a drawback of the process for lower drug concen-
trations. The distribution of the drug within the matrix was
not homogeneous and therefore the percentage of drug
impregnated was found to be higher than that expected
from the calculation of the theoretical amount.
Usually, conventional drug delivery products provide
sharp increases in the drug concentration at potentially
toxic levels, followed by a relatively short period at the
therapeutic level and drug concentration drops until new
administration. In controlled drug delivery systems
designed for long-term administration, the drug level
should ideally follow a proﬁle similar to the one shown
in Fig. 8. From the release experiments we can conclude
that a sustainable release of dexamethasone from the scaf-
folds was achieved for periods over 21 days.
Dexamethasone activity as an inductive agent in osteo-
genic culture systems is relevant. Several studies in the lit-
erature report the in vitro osteogenic diﬀerentiation of
puriﬁed, culture-expanded human MSCs, therefore the
preparation of a scaﬀold able to release an active agent
at a controlled rate, with the appropriate concentration,
is important.
Fig. 9 presents the drug release proﬁle of drug in terms
of the percentage of dexamethasone release as a function of-loaded scaﬀolds prepared by supercritical-assisted ..., Acta Bio-
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Fig. 8. Dexamethasone release proﬁle of the scaﬀolds loaded with (j) 5wt.%; (}) 10wt.% and () 15wt.% drug.
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Fig. 9. Percentage of drug release as a function of time for the system with
(j) 5wt.%; (}) 10wt.% and () 15wt.% dexamethasone.
Fig. 10. Power law applied to the drug release proﬁle of the SPLA samples
loaded with 15wt.% of dexamethasone.
Table 1
Kinetic parameters calculated from the ﬁt of the power law to the
experimental data of drug relase proﬁles
Sample Release exponent, n Kinetic constant, k
SPLA:dex 5wt% 0.62 0.11
SPLA:dex 10wt% 0.63 0.12
SPLA:dex 15wt% 0.62 0.14
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very similar as can be observed. As can also be observed
from the ﬁgure, after 21 days around 80% of the drug
was released.
To better understand the drug release mechanism of the
systems prepared the power law was applied to the experi-
mental data. Power law is a simple empirical equation (see
Eq. (4)), which describes a linear relationship between log-
arithm of the percentage of drug released and logarithm of
time, up to 60% of the maximum drug released [51].
Fig. 10 shows, as an example, the linear ﬁt of the log–log
data related to the release proﬁle of the sample prepared
with 15wt.% of dexamethasone.
The correlation coeﬃcient of the regression was 0.95,
meaning that the power law is adequate to describe the
mechanism of drug release from the SPLA scaﬀolds.
From the ﬁt of Eq. (4) to the experimental data obtained
after the in vitro release studies it is possible to calculate thePlease cite this article in press as: Duarte ARC et al., Dexamethasone
mater (2009), doi:10.1016/j.actbio.2009.01.047kinetic parameters that describe the early stage mechanism
underlying this delivery system. The release exponent n,
indicative of the mechanism of the drug release, was calcu-
lated from the slope of the curve. Additionally, from the
power law it is also possible to derive the kinetic constant
of the system, which is characteristic of properties of the
matrices prepared as it incorporates the structural and geo-
metrical characteristics of the device. The results obtained
for the three samples are presented in Table 1.-loaded scaﬀolds prepared by supercritical-assisted ..., Acta Bio-
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polymeric devices: Fickian diﬀusion and the so-called
case-II transport. Fickian diﬀusional release occurs by the
usual molecular diﬀusion of the drug due to a concentra-
tion gradient. Case-II transport is the mechanism associ-
ated with the relaxation process of the macromolecules
upon water uptake into the polymeric matrix. From the
power law (Eq. (4)), it is possible to conclude that when
the release exponent is 1 the drug release corresponds to
a zero-order kinetic. In this case, and for a thin ﬁlm sample
the governing drug release mechanism is the case-II trans-
port. Another special case is when the release exponent is
0.5, which indicates diﬀusion-controlled drug release.
When calculated n values are between 0.5 and 1 a superpo-
sition of both phenomena (diﬀusional and relaxational
release) occurs and in these cases the mechanism that gov-
erns the drug release is called an anomalous transport. The
power law release exponents calculated from our experi-
ments indicate that the dexamethasone release from the
SPLA scaﬀolds is governed by an anomalous transport,
meaning that both diﬀusion of the drug out of the matrix
and the water uptake and swelling of the polymeric matrix
inﬂuence the drug release.
5. Conclusions
This work evaluated the feasibility of preparing drug-
loaded porous structures of natural based polymeric sys-
tems using a supercritical-assisted phase inversion method.
The loaded SPLA matrices obtained by supercritical-
assisted phase inversion are bicontinuous structures char-
acterized by a rough surface where micropores and mac-
ropores are present. The same type of structures was
obtained for the unloaded SPLA scaﬀolds, meaning that
the presence of dexamethasone did not alter the morphol-
ogy of the three-dimensional scaﬀolds. Diﬀerent concentra-
tions of dexamethasone were loaded in SPLA 50:50
scaﬀolds. From the release proﬁles we can conclude that
dexamethasone release can be sustained for over 21 days
and the modelling of the drug release experimental data
indicates that the release is governed by an anomalous
transport, which comprises not only drug diﬀusion but also
the water uptake of the polymeric matrix.
The preparation of scaﬀolds loaded with a pharmaceuti-
cal agent for tissue engineering purposes using supercritical-
assisted phase inversion has proven to be feasible and a one-
step process was carried out with no need for further drying
processes. We believe that such methodology could be
adapted to prepare porous structures using other natural
based polymeric systems and other bioactive compounds.Acknowledgment
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